ADXS PSA

Drug Profile

ADXS PSA

Alternative Names: ADXS-PSA; ADXS31-142; Live attenuated Listeria-based vaccines for cancer - Advaxis; Lovaxin P; Prostate cancer vaccine - Advaxis

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advaxis
  • Developer Advaxis; Merck & Co
  • Class Cancer vaccines; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; Kallikrein inhibitors; Tumour protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 01 Jun 2018 Interim efficacy and adverse events data from a phase I/II trial in prostate cancer released by Advaxis
  • 21 Dec 2017 Advaxis has patents pending for ADXS PSA in countries worldwide
  • 13 Jun 2017 Efficacy data from a phase-I/II clinical trial in Prostate cancer released by Advaxis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top